Session

Back to Programme Overview

New therapeutic approaches in targeted therapy for renal cell carcinoma

Poster Session 64

  • Location:
    Room Berlin, North Hall (Level 1)
  • Chairs:
     N. Kröger, Greifswald (DE)
     A. Necchi, Milan (IT)
     G. Stewart, Cambridge (GB)
  • Aims and objectives of this session

    To discuss new therapeutic approaches based on basic research results.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
842
Impact of intratumoral heterogeneity of renal cancer on drug response and development of resistance in patient derived xenografts

By: Bedke J.1, Flechsig S.2, Hennenlotter J.1, Wulf-Goldenberg A.2, Jandrig A.3, Schostak M.3, Becker M.2, Fichtner I.2, Zeisig R.2, Hoffmann J.2, Schmees C.4, Stenzl A.1

Institutes: 1University of Tübingen, Dept. of Urology, Tübingen, Germany, 2EPO GmbH, Berlin-Buch, Berlin, Germany, 3University of Magdeburg, Dept. of Urology, Magdeburg, Germany, 4Natural and Medical Sciences Institute, Dept. of Molecular Biology, Reutlingen, Germany

843
Pathological and prognostic significance of densities of CD57+ (natural killer cells), CD68+ (macrophage), and mast cells in renal cell carcinoma tissues

By: Mochizuki Y., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Oba K., Sakai H.

Institutes: Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan

844
A microplate co-culture assay allows individualised compound efficacy testing in patients derived 3D tumour spheroids and autologous immune cells

By: Bedke J.1, Bodenhöfer M.2, Harland N.1, Hennenlotter J.1, Anderle N.2, Schmees C.2, Stenzl A.1

Institutes: 1University of Tübingen, Dept. of Urology, Tübingen, Germany, 2Natural and Medical Sciences Institute At The University of Tübingen, Dept. of Molecular Biology, Reutlingen, Germany

845
Enhanced RCC cell killing with natural killer cells generated from CD34+ hematopoietic progenitor cells combined with mAb cG250

By: Oosterwijk-Wakka J.1, Cany J.2, Sabata Pérez H.1, Dolstra H.2, Mulders P.1, Oosterwijk E.1

Institutes: 1Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 2Radboudumc, Dept. of Hematology, Nijmegen, The Netherlands

846
Orthotopic sunitinib resistant renal cell carcinoma xenograft mouse model

By: Frees S., Moskalev I., Raven P., D’Costa N., Tan Z., Struss W., Chavez-Munoz C., So A.

Institutes: The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

847
Inhibition of semaphorin 3C augments the anti-cancer effect of sunitinib in renal cancer

By: Dejima T.1, Takeuchi A.1, Eto M.1, Naito S.1, Gleave M.2, Ong C.2

Institutes: 1Kyushu University, Dept. of Urology, Fukuoka, Japan, 2The Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada

848
Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

By: Takuto H., Miyake H., Nakano Y., Fujisawa M.

Institutes: Kobe University Graduate School of Medicine, Division of Urology, Dept. of Surgery Related, Kobe, Japan

849
Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo

By: Frees S.1, Chavez-Munoz C.1, Zhou B.1, Raven P.1, Fazli L.1, Chi K.1, Lawson K.2, Finelli A.2, Gleave M.1, So A.1

Institutes: 1The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, 2University of Toronto, Dept. of Surgical Oncology,, Toronto, Canada

850
Metformin drives synergistic effect and overcomes the treatment resistance of molecular targeted drugs for renal cell carcinoma

By: Matsumoto H., Mori J., Shimizu K., Fujii N., Kawai Y., Inoue R., Yamamoto Y., Hirata H., Shimabukuro T., Matsuyama H.

Institutes: Yamaguchi University, Graduate School of Medicine, Dept. of Urology, Ube, Japan

851
Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress

By: Okubo K., Sato A., Asano T., Isono M., Asano T.

Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan

852
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma

By: Abt D.1, Kraus M.2, Bader J.2, Besse A.2, Schmid H.-P.1, Engeler D.S.1, Driessen C.2, Besse L.2

Institutes: 1Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, 2Kantonsspital St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland

853
Ritonavir, a potent inhibitor of P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells

By: Sato A., Asano T., Okubo K., Isono M., Asano T.

Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan

854
Transcriptomic-metabolomic profiling revealed that fatty acid oxidation-induced stress causes cancer Cachexia

By: Fukawa T.1, Yan-Jiang B.C.4, Kanayama H.-O.2, Teh B.T.3, Shyh-Chang N.4

Institutes: 1Tokushima University Graduated School, Dept. of Urology, Tokushima, Japan, 2Tokushima University Graduated School, Dept. Of Urology, Tokushima, Japan, 3National Cancer Centre Singapore, Laboratory of Cancer Epigenome, Singapore, Singapore, 4Genome Institute of Singapore, Agency For Science Technology and Research, Singapore, Singapore

Summary
 G. Stewart, Cambridge (GB)